Intellectual Disability

Summary — Large stem cell clinical trials designed mainly for intellectual disability itself are still hard to find. Relevant information comes mostly from autism research: in a randomised phase II study of 180 children (2020), the investigators presented, as an exploratory analysis, the possibility that results differed depending on whether intellectual disability was present. This does not mean an effect in children with intellectual disability; it shows that results may vary with participant characteristics.

What is intellectual disability?

Intellectual disability involves limitations, beginning in the developmental period, in intellectual functions such as reasoning, problem-solving, learning and judgement, and in the adaptive skills needed for daily life, such as communication, self-care and social participation. It ranges from mild to profound, and the level of support needed varies widely. Diagnosis considers both standardised intelligence testing and assessment of adaptive functioning in real life.

The causes are very diverse: chromosomal or genetic conditions such as Down syndrome or fragile X syndrome, congenital metabolic diseases, infection or exposure to drugs or alcohol during pregnancy, brain injury around birth, and severe infection or trauma in early childhood. In many cases no cause is found even after detailed testing. Because different causes produce different changes in the brain, a single treatment is unlikely to mean the same thing for all forms of intellectual disability.

Current standard support

Support spans the whole life course: early identification and intervention, individualised special education, speech and occupational therapy, training in daily living skills, family support, and vocational and housing support in adulthood. Where a treatable underlying condition exists, such as hypothyroidism or certain metabolic diseases, treating the cause is important. Co-occurring epilepsy, behavioural problems and sleep problems are treated individually.

Why direct stem cell studies are rare

Several factors explain why stem cell studies targeting intellectual disability are rare. First, the causes are so varied that participants are hard to group into a single study population. Second, where the cause is genetic, giving cells is unlikely to change the cause itself. Third, changes in intellectual and adaptive functioning are strongly influenced by years of development and education, making the effect of cell administration particularly hard to measure separately.

What was reported in autism research

A Duke University team followed a phase I study of autologous cord blood in 25 autistic children (2017) with a randomised, placebo-controlled phase II study of 180 children aged 2–7 (2020). In the phase II study there was no significant difference in the primary outcome, a socialisation score, across the whole group. In an exploratory analysis limited to children without intellectual disability, the investigators reported differences in some communication and EEG measures.

This can be read in two ways: as a hypothesis that responses to cord blood may differ depending on whether intellectual disability is present, or as a difference that appeared by chance in a subgroup analysis. A separate study planned for this purpose from the outset is needed to tell which. Either way, the result cannot be taken as an effect on intellectual disability.

Safety and points to note

In clinical trial settings, intravenous cord blood has generally been associated with mild-to-moderate adverse events. However, stem cell interventions offered outside research, without verified quality control or ethical review, have been associated with risks such as infection, and the U.S. Food and Drug Administration (FDA) urges consumers to be cautious. The International Society for Stem Cell Research (ISSCR) warns against the sale of unproven stem cell interventions and states that clinical use should go through rigorous clinical trials.

Open questions

For cell therapy research to yield meaningful results in intellectual disability, studies would need to group participants by cause and use controlled designs that account for long-term development and the effects of education and rehabilitation. Studies testing the subgroup hypothesis raised in autism research are also needed. For now, education, rehabilitation and daily-living support remain at the centre of support for intellectual disability.

How intellectual and adaptive functioning are measured

Diagnosis and research in intellectual disability assess two areas together. The first is intellectual functioning, measured with standardised intelligence tests such as the Wechsler Intelligence Scale for Children (WISC), which assess verbal comprehension, reasoning, working memory and processing speed and express results as an IQ compared with the average for the same age. The second is adaptive functioning, assessed with tools such as the Vineland Adaptive Behavior Scales covering communication, daily living skills, socialisation and motor skills; this scale was also a primary outcome in autism stem cell research.

Because these assessments compare children with age-based norms, scores can change naturally as children grow. The child's condition on the day, the examiner and familiarity from repeated testing also affect results. Treatment studies therefore need designs that compare with a control group or test whether a child's change exceeds typical developmental progress. Meaningful changes in intellectual functioning usually emerge over years, so conclusions cannot easily be drawn from short studies.

How to look up clinical trial information

Ongoing and completed clinical trials can be checked on public registries. ClinicalTrials.gov, run by the U.S. National Library of Medicine, and jRCT, run by Japan's Ministry of Health, Labour and Welfare, publish each study's purpose, eligibility criteria, intervention, outcomes, institutions and status. Results are later published as journal papers, and the reference links at the bottom of this page lead to the original information. It is also worth knowing that interventions not publicly registered are difficult to verify from outside, in both design and results.

The above summarises results reported in published papers and public-agency materials. University and institute names are given to identify research sources, not to introduce or recommend any medical institution. Reported results do not mean the same effect for everyone, and the suitability of any treatment is decided by the medical team.

Autism, Developmental Disorders & Cerebral Palsy →